-(glutathion-S-yl)-N-methyl-␣-methyldopamine (5-GS-N-Me-␣-MeDA), the caffeic acid metabolite 2-(glutathion-S-yl)-caffeic acid (2-GS-CA), and four GSH conjugates of 2-hydroxy (OH) and 4-OH estrogens (GS estrogens). MRP1-mediated E
Nine multidrug resistance proteins (MRPs) belong to the "C" subfamily of the ATP-binding cassette (ABC) transporter superfamily, and although they share moderate sequence identity (30 -50%), their substrate specificities only partially overlap (Haimeur et al., 2004) . With the exception of the liver, MRP1 is ubiquitously expressed, and in polarized cells it is almost always found on basolateral membranes (Leslie et al., 2005) . However, in endothelial cells at the blood-brain barrier, it is expressed on apical membranes (Dallas et al., 2006) . Physiologically, MRP1 mediates the release of the proinflammatory mediator leukotriene C 4 (LTC 4 ) from mast cells (Wijnholds et al., 1997; Bartosz et al., 1998) . It also has an established role in mediating the efflux of conjugated phase II metabolites, including many but not all glucuronide, sulfate, and glutathione (GSH) conjugates (Haimeur et al., 2004; Leslie et al., 2005) .
MRP2 shares 49% sequence identity with MRP1; however, unlike MRP1, it is expressed in a limited number of tissues such as liver, kidney, and placenta and in polarized cells it localizes to apical membranes (Leslie et al., 2005) . The most important physiological role of MRP2 is mediating the biliary excretion of organic anion conjugates, primarily bilirubin glucuronides Leslie et al., 2005) . Despite the differences in their membrane and tissue localization, MRP1 and MRP2 transport many of the same conjugated metabolites, including LTC 4 and 17␤-estradiol 17-(␤-Dglucuronide) (E 2 17␤G). However, the relative affinity of MRP2 for these metabolites is significantly lower than the affinity of MRP1 König et al., 1999) .
The ring-substituted methamphetamine derivative, methylenedioxymethamphetamine (MDMA, ecstasy) (Fig. 1A) , is a popular drug of abuse among Western youth. Although systemic administration of MDMA to rats leads to selective serotonin neurotoxicity, direct injection of MDMA or one of its primary catechol metabolites, ␣-methyldopamine, fails to produce any long-lasting neurotoxic effects (McCann and Ricaurte, 1991) . It has now been established that GSH-conjugated metabolites of MDMA contribute to the observed neurotoxicity. Thus, administration of the GSH conjugate 5-(glutathion-S-yl)-N-methyl-␣-methyldopamine (5-GS-N-Me-␣-MeDA) to rats reproduces both the behavioral and short-term alterations in brain catecholamine levels observed after systemic MDMA administration (Miller et al., 1996) . Little is known about the disposition of MDMA metabolites, but previous research has suggested that a GSH conjugate uptake mechanism present at the blood-brain barrier is probably involved (Bai et al., 2001) .
Caffeic acid (3,4-dihydroxycinnaminic acid, CA) (Fig. 1B) is a nonflavonoid catecholic acid found in relatively large quantities in fruits and vegetables. Absorbed CA appears to be mainly glucuronidated, sulfated, or O-methylated to ferulic acid (Mateos et al., 2006) . Incubation of CA with liver microsomes and isolated hepatocytes also leads to the formation of several GSH conjugates (Galati et al., 2002; Moridani et al., 2002) . Both mono-and di-substituted GSH conjugates of caftaric acid and CA are present in relatively high amounts in grape juice and wine (Singleton et al., 1985) . Otherwise, little is known about the metabolism and disposition of CA and its metabolites. However, CA can act as an anti-inflammatory agent by inhibiting 5-lipoxygenase, which in turn inhibits the synthesis of proinflammatory cytokines, such as the MRP1 substrate LTC 4 (Koshihara et al., 1984) .
Catechol estrogens (Fig. 1C) , although structurally dissimilar from MDMA metabolites or CA, have a similar potential to form conjugates with GSH when oxidized to their corresponding quinones (Butterworth et al., 1996) . Prolonged exposure to catechol estrogens is thought to play a role in carcinogenesis, although the underlying mechanisms are unknown. However, 4-OH estrogen quinones are known to form covalent adducts with guanine, leading to depurinating DNA adducts (Roy and Liehr, 1999; Yue et al., 2003; Abel et al., 2004) . Furthermore, catechol estrogens can enhance endogenous DNA adduct formation and free radical generation attributable to redox cycling between the catechol and quinone forms, which ultimately leads to DNA damage (Roy and Liehr, 1999; Yue et al., 2003) .
Beyond the shared ability of the three chemically distinct groups of catechol metabolites described above to form conjugates with GSH, relatively little is known about their further disposition. However, it is reasonable to presume that some membrane transport proteins are involved. Because both MRP1 and MRP2 play important roles in the FIG. 1. Metabolic pathways and chemical structures of the GSH-conjugated catechol metabolites examined in the present study. Shown are (A) MDMA, its primary phase I metabolite N-Me-␣-MeDA, and its GSH conjugate 5-GS-N-Me-␣-MeDA; (B) CA and its GSH conjugate 2-GS-CA; (C) 17␤-estradiol and two phase I metabolites, 2-OH-17␤-estradiol (2-OH-E 2 ) and 4-OH-17␤-estradiol (4-OH-E 2 ), and some of their corresponding GSH-conjugated metabolites, 2-OH-1-GS-E 2 , 2-OH-4-GS-E 2 , and 4-OH-2-GS-E 2 . Demethylation of MDMA by CYP2D, CYP2B, and CYP3A yields N-Me-␣-MeDA. Hydroxylation of 17␤-estradiol by CYP1A yields 2-OH-E 2 , and hydroxylation by CYP1B yields 4-OH-E 2 . distribution and elimination of a variety of GSH conjugates, we investigated the ability of GSH-conjugated catechol metabolites of MDMA, CA, and estrogens to interact with MRP1 and MRP2 by testing whether they could modulate the transport activity of these homologous transporters in vitro, using the model substrates LTC 4 and E 2 17␤G.
Materials and Methods
Materials. [14,15,19,20- 3 H]LTC 4 (194.6 and 166.8 Ci/mmol) and [6, H]E 2 17␤G (53.0 and 46.9 Ci/mmol) were purchased from PerkinElmer Life and Analytical Sciences (Woodbridge, ON, Canada). LTC 4 was purchased from Calbiochem (San Diego, CA). Creatine kinase and creatine phosphate were obtained from Roche Diagnostics (Laval, QC, Canada). AMP, ATP, CA, and E 2 17␤G were purchased from Sigma-Aldrich (St. Louis, MO). Monoclonal antibody M 2 I-4, specific for MRP2, was purchased from Alexis Laboratories (San Diego, CA). Monoclonal antibody QCRL-1, specific for MRP1, was derived in this laboratory (Hipfner et al., 1994) . 2-and 4-OH-17␤-estradiol and 2-OH-17␤-estrone were purchased from Steraloids (Newport, RI). N-Me-␣-MeDA was synthesized by standard procedures. Briefly, MDMA was demethylated with a 2-fold molar excess of boron trichloride in methylene chloride under argon. MDMA was kindly provided by the Research Technology Branch, National Institute on Drug Abuse (Rockville, MD). All other chemicals and reagents were of analytical grade.
Synthesis of Catechol GSH Conjugates. GSH conjugates of CA, N-Me-␣-MeDA, 2-OH-17␤-estradiol, and 4-OH-17␤-estradiol were prepared as described previously (Butterworth et al., 1996; Jones et al., 2005) . Briefly, each parent catechol compound was oxidized to its corresponding quinone using sodium periodate. Quinones were further reacted with excess GSH. The resulting conjugates were then purified by reverse-phase semipreparative highperformance liquid chromatography [LC-6A (Shimadzu, Kyoto, Japan) and Ultrasphere ODS-5 (Beckman Coulter, Fullerton, CA) columns] and characterized by their retention times and ultraviolet-visible spectroscopic parameters (Butterworth et al., 1996; Cao et al., 1998) . The identity of the purified conjugates was confirmed by electrospray ionization-mass spectrometry (Southwest Environmental Health Sciences Center Proteomics Facility Core, Tucson, AZ).
Cell Culture and Transfection of MRP1 and MRP2 Expression Vectors. pcDNA3.1(Ϫ) expression vectors containing human MRP1 and MRP2 cDNAs were transfected into simian virus 40-transformed human embryonic kidney (HEK293T) cells (Létourneau et al., 2007) . Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 4 mM l-glutamine and 7.5% fetal bovine serum. Approximately 18 ϫ 10 6 cells were seeded per 150-mm plate; 24 h later cells (at 60 -85% confluence) were transfected with 20 g of DNA using 50 l of Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. After 48 h at 37°C, the cells were collected, snap-frozen in liquid nitrogen, and stored at Ϫ80°C until needed.
Membrane Vesicle Preparation and Determination of MRP1 and MRP2 Protein Expression Levels. Pellets of transfected cells were thawed and disrupted by argon cavitation at 300 psi, and membrane vesicles were prepared as described previously (Loe et al., 1996b; Létourneau et al., 2007) . Membrane vesicles were aliquoted and stored at Ϫ80°C. Vesicular protein concentrations were determined using the Bradford method (Bio-Rad Laboratories, Mississauga, ON, Canada) with bovine serum albumin as the standard. Levels of MRP1 and MRP2 protein expressed by the transfected cells were determined by immunoblot analysis. Briefly, proteins were resolved on a 7% SDS-polyacrylamide gel and electrotransferred to polyvinylidene difluoride membranes (Pall Corporation, Pensacola, FL). Membranes were subsequently blocked with 4% (w/v) skim milk powder in Tris-buffered saline containing 0.1% Tween 20 (TBS-T) for 1 h followed by overnight incubation at 4°C with the human MRP1-specific murine monoclonal antibody QCRL-1 (1:10,000) or the MRP2-specific murine monoclonal antibody M 2 I-4 (1:10,000) in blocking solution (Létourneau et al., 2007) . After washing with TBS-T, immunoblots were incubated with horseradish peroxidase-conjugated goat anti-mouse antibody (Pierce, Edmonton, AB, Canada) in blocking solution, followed by application of Western Lightning chemiluminescence blotting substrate (PerkinElmer Life and Analytical Sciences) and exposed to film (Ultident, St. Laurent, QC, Canada).
MRP-Mediated Transport of
3 H-Labeled LTC 4 and E 2 17␤G by Membrane Vesicles. ATP-dependent uptake of the 3 H-labeled organic anion substrates LTC 4 and E 2 17␤G by MRP1-and MRP2-enriched membrane vesicles was measured using a 96-well format rapid filtration technique as described previously (Létourneau et al., 2007) . All reactions were carried out in a final reaction volume of 30 l in 250 mM sucrose and 50 mM Tris-HCl (pH 7.4) buffer (TSB), containing AMP or ATP (2 mM), MgCl 2 (10 mM), creatine phosphate (10 mM), creatine kinase (100 g/ml), and catechol conjugates at the concentrations specified. Uptake was stopped by rapid dilution in ice-cold TSB and subsequent filtration using a FilterMate Harvester and Unifilter-96 GF/B filter plate apparatus (Packard BioScience, Meriden, CT). Radioactivity on the filters was quantified by liquid scintillation counting. All data were corrected for the amount of 3 H-labeled substrate that remained bound to the filter, which was usually Ͻ10% of the total radioactivity. Transport in the presence of AMP was subtracted from transport in the presence of ATP to determine ATP-dependent uptake. All transport assays were performed in duplicate or triplicate (when indicated), and results are expressed as means Ϯ S.D.
For MRP1-mediated LTC 4 uptake, 2 g of vesicle protein was incubated with [ 3 H]LTC 4 (50 nM, 10 nCi) for 60 s at 23°C. MRP1-mediated E 2 17␤G uptake was measured by incubating 2 g of vesicle protein with [ 3 H]E 2 17␤G (400 nM, 20 nCi) for 60 s at 37°C. For MRP2-mediated E 2 17␤G uptake, 6 g of vesicle protein was incubated with [ 3 H]E 2 17␤G (400 nM, 40 nCi) for 5 min at 37°C (Létourneau et al., 2007) . MRP1-mediated E 2 17␤G uptake kinetics were typically measured by incubating 2 g of vesicle protein with a range of [ 3 H]E 2 17␤G concentrations (100 nM-30 M) (40 nCi) for 60 s at 37°C in the presence or absence of catechol conjugates at the concentrations indicated.
Data Analysis. IC 50 and kinetic parameters were computed using GraphPad Prism 3.0 software (GraphPad Software Inc., San Diego, CA). When shown, error bars represent the S.D. from the mean. Fig. 1 could modulate MRP1-mediated transport of E 2 17␤G or LTC 4 , uptake assays were performed using MRP1-enriched membrane vesicles prepared from transiently transfected cells. Levels of MRP1 expression in membrane vesicles were determined by immunoblot analysis before transport experiments ( Fig. 2A) . As shown in When the effects of GSH-conjugated estrogen catechols were examined, each of the four metabolites was found to inhibit both E 2 17␤G (Fig. 4, A-D) and LTC 4 (Fig. 4 , E-H) uptake in a concentration-dependent fashion with all IC 50 values less than 2 M. The IC 50 values from multiple repeat experiments are summarized in Table 1 .
Results

Modulation of MRP1-Mediated
Kinetic Parameters of MRP1-Mediated [ 3 H]E 2 17␤G Transport in the Presence of GSH-Conjugated Catechol Metabolites. To determine more precisely how GSH-conjugated catechol metabolites modulate MRP1-mediated E 2 17␤G transport, the kinetic parameters of E 2 17␤G uptake were determined in the presence (or absence) of two concentrations of 5-GS-N-Me-␣-MeDA (30 and 100 M), 2-GS-CA (3 and 10 M), and 2-OH-1-GS-E 2 (0.3 and 1 M) (Fig. 5) . As shown in Fig. 5A , 5-GS-N-Me-␣-MeDA competitively inhibited E 2 17␤G transport by MRP1 as the apparent K m of E 2 17␤G increased from 1.6 to 9.2 M in the presence of 100 M of the metabolite, whereas the V max remained relatively unchanged. 2-GS-CA and 2-OH-1-GS-E 2 similarly inhibited MRP1-mediated E 2 17␤G transport in a competitive manner (Fig. 5, B and C) . The K i values for the inhibition of MRP1-mediated E 2 17␤G transport by 5-GS-N-Me-␣-MeDA, 2-GS-CA, and 2-OH-1-GS-E 2 are summarized in Table 2 .
Modulation of MRP2-Mediated [ 3 H]E 2 17␤G Transport by GSHConjugated Catechol Metabolites. We also investigated whether the GSH-conjugated catechol metabolites could inhibit MRP2-mediated transport. Vesicular uptake experiments were performed using membrane vesicles prepared from transiently transfected HEK cells and the expression of MRP2 was confirmed by immunoblot analysis before transport experiments as before (Fig. 2B) . As shown in Fig. 6, A and B, the MDMA and CA metabolites inhibit MRP2-mediated E 2 17␤G uptake in a concentration-dependent fashion, with IC 50 values ranging from 10 to 145 M. Similar to MRP1, the corresponding N-acetylcysteine conjugates [5-(N-acetylcystein-S-yl)-N-methyl-␣-methyldopamine and 5-(N-acetylcystein-S-yl)-caffeic acid] had no effect on either E 2 17␤G or LTC 4 uptake by MRP2 (data not shown). When the effects of the GSH-conjugated estrogen catechols were examined (Fig. 6, C-F) , the 2-OH-1-GS-E 2 and 2-OH-1-GS-E 1 metabolites potently inhibited E 2 17␤G uptake by MRP2 with IC 50 values of 2.1 and 1.6 M, respectively, whereas the 2-OH-4-GS-E 2 and 4-OH-2-GS-E 2 conjugates were approximately 50-and 300-fold less potent (IC 50 values of approximately 95 and 580 M, respectively). A summary of IC 50 values from multiple repeat experiments is provided in Table 3 .
Discussion
The potential of several structurally diverse GSH-conjugated catechol metabolites to modulate the transport activity of MRP1 and MRP2 was investigated to gain insight into which of these ABC transporters might be involved in the disposition of these metabolites in vivo. The results presented here show for the first time that GSH-conjugated catechol metabolites of MDMA, CA, and estradiol are inhibitors of MRP1 and MRP2.
In general, the six GSH conjugates were more potent at inhibiting MRP1-mediated E 2 17␤G transport than LTC 4 transport. This finding could be expected because MRP1 exhibits a 15-fold higher affinity for LTC 4 than for E 2 17␤G (Loe et al., 1996a) . The GSH conjugates were also more potent at inhibiting MRP1-than MRP2-mediated E 2 17␤G transport. This observation was again not surprising, because MRP1 exhibits a 5-and 10-fold higher affinity for E 2 17␤G and LTC 4 than for MRP2, respectively König et al., 1999) . Lastly, the N-acetylcysteine conjugates investigated had no observable effect (up to 1 mM) on MRP1-or MRP2-mediated vesicular transport, as would be expected, as previous studies have demonstrated the critical importance of the ␥-glutamyl residue of GSH for interaction with these transporters (Loe et al., 1996b; Leslie et al., 2003) .
Many experimental inhibitors of MRP1 and related proteins have been described previously, but very few of them are highly specific 
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at ASPET Journals on April 9, 2017 dmd.aspetjournals.org for MRP1 or its homologs (Boumendjel et al., 2005) . One exception is the highly potent and specific tricyclic isoxazole inhibitor LY475776 that inhibits LTC 4 transport by MRP1 with an IC 50 of 50 nM (in vitro) in the presence of millimolar concentrations of GSH (Mao et al., 2002) . The widely used inhibitor MK571 is considerably less potent than LY475776 and also inhibits MRP2 (and other MRPs), whereas LY475776 does not (Gekeler et al., 1995; Mao et al., 2002) .
In addition to small molecule modulators, established substrates of MRP1 and MRP2, e.g., E 2 17␤G, are often competitive inhibitors of the transport of other substrates (Loe et al., 1996a; Dantzig et al., 2004) . In the present study, all six GSH-conjugated catechol metabolites were shown to inhibit both E 2 17␤G and LTC 4 transport by MRP1, and, in the case of E 2 17␤G, inhibition was demonstrated to be competitive. The observed IC 50 and K i values both showed a rank order of inhibitory potency of the metabolites as glutathion-S-yl (GS) estrogens Ͼ 2-GS-CA Ͼ 5-GS-N-Me-␣-MeDA (Table 1 ). This rank order was similar for inhibition of MRP2-mediated transport with the notable exception that 2-OH-4-GS-E 2 and 4-OH-2-GS-E 2 were markedly less potent (50-and 300-fold, respectively) than 2-OH-1-GS-E 1 or 2-OH-1-GS-E 2 (Table 3) . This difference in inhibitory potency for MRP1 and MRP2 was somewhat surprising because the estrogen conjugates are structurally quite similar to one another and their potencies were comparable with respect to inhibition of MRP1-mediated transport (Table 1) . Further studies are ongoing to elucidate whether the catechol metabolites exert their inhibitory effects simply by binding to MRP1 or MRP2 without being transported or by competing for active transport. at ASPET Journals on April 9, 2017 dmd.aspetjournals.org MDMA was first identified as a potential neurotoxicant in 1986 and, much later, the cysteinyl-S-conjugates of primary MDMA metabolites were shown to be the causative agents (Stone et al., 1986; Miller et al., 1996) . Neurotoxicity was observed at nanomolar concentrations, and increases in brain concentrations of the conjugates were shown to be directly proportional to the amount of selective serotonergic neurotoxicity observed (Jones et al., 2005) . Furthermore, GSH was shown to modulate the entry of GSH-conjugated metabolites of MDMA into rat brains, and GSH-conjugated metabolite degradation could be prevented by inhibiting the ectoenzyme ␥-glutamyltranspeptidase with acivicin (Bai et al., 1999) . GSH-conjugated metabolites of MDMA are also detected in the bile of rats after systemic administration of this agent (Bai et al., 2001 ). As MRP2 is the predominant canalicular GSH conjugate efflux transporter, it seems likely that it mediates this transport, although in vivo studies are needed to confirm this theory. On the other hand, because hepatocytes do not normally express significant levels of MRP1 (Leslie et al., 2005) , 
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at ASPET Journals on April 9, 2017 dmd.aspetjournals.org another transporter seems likely to be responsible for the basolateral efflux of GSH-conjugated MDMA metabolites into the blood circulation. However, the identity of this hepatic transporter remains unknown. At the blood-brain barrier, several MRP-related proteins, including MRP1, have been localized to the apical membrane of endothelial cells as well as in astrocytes (Dallas et al., 2006) . Thus, it has been proposed that these MRPs may play a role in preventing the accumulation of toxic GSH conjugates in the brain. However, if MDMA metabolites are inhibitors of MRP-mediated transport in vivo, they may account for increased brain concentrations as their efflux activity is inhibited. The results of the present study show for the first time that MRP1 and MRP2 can interact with 5-GS-N-Me-␣-MeDA, at least in vitro and may thus be involved in the disposition of this neurotoxic metabolite in vivo.
It is presumed that CA is metabolized to 2-GS-CA, although the extent to which this metabolism occurs is not known. In the present study, 2-GS-CA proved to be a moderately potent inhibitor of MRP1-mediated E 2 17␤G and LTC 4 transport with IC 50 values of 3 and 20 M, respectively. Like 5-GS-N-Me-␣-MeDA, 2-GS-CA was more potent at inhibiting E 2 17␤G than LTC 4 . Similarly, 2-GS-CA more M 5-GS-N-Me-␣-MeDA 145 Ϯ 46 (3) 2-GS-CA 9.6, 10.2 2-OH-1-GS-E 2 2.1 Ϯ 1.0 (3) 2-OH-1-GS-E 1 1.6 Ϯ 1.1 (4) 2-OH-4-GS-E 2 97, 91 4-OH-2-GS-E 2 582 Ϯ 144 (3) 558 SLOT ET AL.
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potently inhibited E 2 17␤G transport by MRP1 than by MRP2 (IC 50 of 3 versus 10 M). Relatively little is known about the metabolism and distribution of CA or its metabolites. Although CA is metabolized to dihydrocaffeic acid and ferulic acid, these compounds may be converted back to CA by hydrogenase activity and CYP1A activity, respectively (Moridani et al., 2002) . However, this cycle is disrupted when CA is conjugated to GSH, and this conjugation reaction appears to be preceded by metabolic activation of CA by CYP2E1 (Fig. 1B ) (Moridani et al., 2002) . Our data are the first to demonstrate that the GSH conjugate of CA can inhibit MRP1-mediated transport of LTC 4 . CA noncompetitively inhibits 5-lipoxygenase activity, which is critical for biosynthesis of LTC 4 and other leukotrienes (Koshihara et al., 1984) . Thus, the anti-inflammatory actions of CA and its metabolites may be 2-fold. They may inhibit both the formation of LTC 4 through action on 5-lipoxygenase and release of LTC 4 via MRP1 from proinflammatory cells. Further study is needed to determine human plasma concentrations of this conjugated GSH catechol metabolite to establish whether its ability to inhibit MRP1-mediated LTC 4 transport in vitro is physiologically relevant for the anti-inflammatory potential of CA.
Catechol estrogens have been associated with an increased risk of breast and endometrial cancers Yue et al., 2003; Doherty et al., 2005) . However, the biological properties of their corresponding GSH conjugates have not been thoroughly investigated, although several GSH-conjugated estrogens have been detected in tumor tissues (Devanesan et al., 2001; Rogan et al., 2003; Yue et al., 2003) . On the other hand, administration of 2-OH-4-GS-E 2 or 2-OH-1-GS-E 2 to Syrian hamsters can produce mild nephrotoxicity. Moreover, repeated daily administration of 2-OH-4-GS-E 2 causes a sustained elevation in urinary markers of renal damage and in the concentration of renal protein carbonyls and lipid hydroperoxides (Butterworth et al., 1998) . Because catechol estrogens are conjugated with GSH (Roy and Liehr, 1999; Bolton et al., 2000; Yue et al., 2003) , it is likely that there is a physiological system in place that prevents these conjugates from accumulating to toxic levels. In addition to endogenous catechol estrogens, GSH conjugates are also formed from equine estrogens that are often used for hormone replacement therapy (Zhang et al., 2001) . Furthermore, disruption of the cellular efflux of GSH catechol estrogen metabolites may exacerbate the carcinogenic potential of 4-OH estrogens as many GSH conjugates retain their ability to produce reactive oxygen species and form covalent adducts (Roy and Liehr, 1999; Bolton et al., 2000; Yue et al., 2003) . Thus, knowledge of the transporters involved in the disposition of both exogenous and endogenous catechol estrogen GSH conjugates is of interest.
Whereas all four of the estrogen conjugates tested were potent inhibitors of MRP1-mediated E 2 17␤G transport (IC 50 0.08 -0.29 M) (Table 1) , only the two metabolites conjugated at the 1-position of the steroid nucleus strongly inhibited MRP2 transport (IC 50 1.6 -2.1 M), compared with those conjugated at position 2 (IC 50 582 M) and position 4 (IC 50 94 M) (Table 3) . Thus, the 4-GS and 2-GS conjugates were approximately 300-and 1500-fold less potent at inhibiting MRP2-mediated E 2 17␤G transport than MRP1, compared with 10-to 20-fold for the 1-GS conjugates. Whether any of these conjugates interact with MRP2 at a substrate binding site and/or an allosteric binding site remains to be elucidated. Nevertheless, it seems apparent that the 2-OH-4-GS-E 2 and 4-OH-2-GS-E 2 conjugates interact in a different way with the substrate and/or modulatory binding sites of MRP2 than metabolites conjugated at position 1 (2-OH-1-GS-E 2 and 2-OH-1-GS-E 1 ).
In summary, the results of this study show that several structurally and biologically distinct classes of both endogenous and exogenous GSH-conjugated catechol metabolites can inhibit both MRP1-and MRP2-mediated transport in vitro. However, the potencies of the metabolites vary substantially, most notably with respect to the 2-GS and 4-GS estrogen conjugates. Thus, all six conjugates are potential substrates for MRP1, and to a lesser extent, MRP2. Studies aimed to determine whether these metabolites are simply modulators of MRP1 and MRP2 or whether they compete for substrate transport are currently underway. Furthermore, it should be noted that our studies do not exclude the possibility that these metabolites could interact with other ABC proteins such as ABCG2 and MRP3 (ABCC3), but this remains to be tested experimentally (Suzuki et al., 2003; Haimeur et al., 2004; Leslie et al., 2005) . Because the parent compounds and some of the metabolites themselves exert biological effects in humans, understanding the activities of these and other metabolites is crucial to understanding their full pharmacological and toxicological potential.
